Moderna has been ordered to pay almost £44,000 after 12-year-olds were encouraged to join Covid vaccine trials with the ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

A complainant shared four third-party posts on X (formerly Twitter) and two online articles with the PMCPA to make the case ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV ... candidate can successfully crea Reports third quarter revenues of $1.9 billion, GAAP net income ...

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...

Moderna has been awarded approximately ... expands the clinical data supporting the use of mRNA vaccines that may be needed if other influenza strains emerge with pandemic potential." MORE: What 3rd ...

Since 2023, Moderna has been studying a vaccine to keep people from getting ... (Updates with background starting in third paragraph.) ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.